Skip to content
Screener

Alkermes ALKS Total costs & expenses

Total costs & expenses at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$8.89B-15.3%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$732.3M-23.2%
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
$254.56M+42.7%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$370.24M+18.6%
AbbVie logo
AbbVieABBV
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX

Other financials

Income statement

See full
Revenue$496.0M+27.0%
Gross profit$397.9M+16.6%
Operating income$18.4M-80.3%
Net income$501.0K-99.4%
EPS (diluted)$0.00-100%

Balance sheet

See full
Cash & equivalents$511.5M-1.9%
Total debt$1.6B+2,064%
Total equity$1.8B+11.3%
Total assets$4.4B+95.0%

Cash flow

See full
Operating cash flow-$165.7M-268%
CapEx$8.1M-37.4%
Free cash flow-$169.8M-291%

Valuation

See full
Market cap$8.32B+89.9%
Enterprise value$9.38B+139%
P/E125.9×+113×
P/S+2.1×

Profitability

See full
Gross margin84.6%-0.6pp
Operating margin7%-17.8pp
Net margin4%-19.2pp
FCF margin14.2%-17.6pp

Returns & leverage

See full
Return on equity3.9%-20.1pp
Debt / equity0.9×+0.8×
Current ratio2.3×-0.9×

Where this comes from

Reported directly by Alkermes in its filing.

Tagged under the XBRL concept us-gaap:CostsAndExpenses.

The source filing: Alkermes’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 9:22 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-319022
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Selling, general and administrative217,625170,849482,218342,553
Change in fair value of contingent consideration26,41426,414
Amortization of acquired intangible assets22,58534,260
Total expenses477,656297,679918,847590,397
OPERATING (LOSS) INCOME18,35392,978(29,927)106,770
OTHER (EXPENSE) INCOME, NET:
Interest income5,34411,09013,88321,231
Interest expense(25,925)(46,817)

Item 1. Condensed Consolidated Financial Statements:

FAQ

What is Alkermes's total costs & expenses?
Alkermes (ALKS) reported total costs & expenses of $477.66M in Q2 2026.
How has Alkermes's total costs & expenses changed year-over-year?
Alkermes's total costs & expenses increased by 60.5% year-over-year, from $297.68M to $477.66M.
What is the long-term trend for Alkermes's total costs & expenses?
Over 4 years (2021 to 2025), Alkermes's total costs & expenses has grown at a 0.4% compound annual growth rate (CAGR), from $1.2B to $1.22B.
What does total costs & expenses mean?
Total costs and expenses aggregate all operating costs, including cost of revenue, R&D, and SG&A, as well as any other operating charges. This metric provides a comprehensive view of the company's total operational footprint. It is used to determine the overall efficiency of the business model in converting revenue into operating profit.

Ask your AI about Alkermes's total costs & expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude